Bristol-Myers Squibb’s KRAS inhibitor Krazati has been approved for a second indication, colorectal cancer (CRC), which could inject some much-needed sales growth into the product.
Jazz Pharmaceuticals has agreed another pipeline-building deal, this time paying $10 million upfront for rights to a KRAS inhibitor programme from UK biotech Redx Pharma,
After months of speculation about a possible takeover of Mirati Therapeutics, Bristol-Myers Squibb has reached a deal to buy the company and its KRAS inhibitor Krazati in
Mirati Therapeutics chief executive David Meek has agreed to step down by mutual agreement with the company's board, to be replaced on a temporary basis by founder and for
Mirati Therapeutics’ hopes of an EU approval for its KRAS inhibitor Krazati in the EU have been thrown into disarray after the EMA’s human medicines committee rejected the